Theralase Technologies Inc. closed a C$17.3 million public offering of common shares and warrants.
The Toronto-based pharmaceutical company sold 57,500,000
The funds will be used to advance studies of the company's treatment for bladder cancer which has shown promise, among other things.
Mackie Research Capital Corp. was the lead agent and sole book runner for the offering.
